Viral Vector And Plasmid DNA Manufacturing Market Trends, Revenue and Future Outlook
Viral Vector and Plasmid DNA Manufacturing Market Growth, Size, Trends Analysis - By Vector Type, By Workflow, By Application, By End Use, By Disease - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Apr-2025 | Report ID: HLCA25100 | Pages: 1 - 261 | Formats*: |
| Category : Healthcare | |||
Viral Vector and Plasmid DNA Manufacturing Market Introduction and Overview
According to SPER Market Research, the Global Viral Vector and Plasmid DNA Manufacturing Market is estimated to reach USD 41.3 billion by 2034 with a CAGR of 20.46%.
The report includes an in-depth analysis of the Global Viral Vector and Plasmid DNA Manufacturing Market, including market size and trends, Interface mix, Applications, and supplier analysis.
Viral vector and plasmid DNA manufacturing are critical processes in gene therapy, vaccine development, and cell-based treatments, enabling the delivery of genetic material into target cells for therapeutic applications. The market is experiencing rapid growth due to increasing demand for gene and cell therapies, advancements in biotechnology, and the rise of mRNA-based vaccines. The expansion of clinical trials and regulatory approvals for gene therapies has further fueled the need for high-quality viral vectors and plasmid DNA production. However, challenges such as high manufacturing costs, scalability issues, stringent regulatory requirements, and the complexity of vector design hinder widespread adoption. Additionally, ensuring consistent quality and reducing production timelines remain key areas for innovation in this rapidly evolving sector.
By Vector Type Insights: Based on the vector type, the adeno-associated virus (AAV) segment led the market with a largest revenue share of 20% in 2024. AAVs are in huge demand and their utilization in clinical trials is increasing rapidly as these viruses offer maximum precision in delivering the gene to the region of interest. The increasing adoption is due to clinical trials relating to the development of orthopedic and ocular gene therapy therapies exhibiting increased efficiency and efficacy. In August 2022, an article published in Springer stated that AAV-mediated gene therapy could prevent acquired hearing loss. Application of AAV is rising significantly across various therapeutic areas, thereby witnessing a boost in its adoption rate.
By Workflow Insights: Based on workflow, the downstream processing segment dominated the market in 2024, owing to the very complicated procedures used to polish and purify clinical grade end goods. Due to the growing demand for clinical-grade viral vectors, producers are working to create new, cost-effective downstream methods to overcome the difficulties posed by traditional lab-scale vector production, which should help the market expand. For instance, integrating traditional and innovative technologies for vector purification with a fed-batch fermentation method and genetically modified cell systems.
By Application Insights: The market was dominated by the vaccinology segment in 2024, according to the application. This growth is mostly driven by the growing need for vaccinations against infectious diseases like COVID-19 and cancer, among other ailments. Plasmid DNA and viral vectors are frequently utilized in vaccine creation, and the growing focus on vaccine research and development is anticipated to propel the expansion of this market niche. Furthermore, the expansion of the application of vaccines in the market for viral vectors and plasmid DNA production is being aided by the availability of government funding for vaccine development programs.
By End Use Insights: In 2024, the research institutes segment led the market based on end use. The segment is being driven by research efforts conducted by research entities related to improving vector production.
By Disease Insights: In 2024, the cancer segment led the market based on disease. Globocan predicts that due to the adoption of a western lifestyle, increased alcohol and tobacco use, poor dietary choices, and physical inactivity, the number of new cancer cases will increase by 47% from 2020 to 28.4 million during the following 20 years. It is anticipated that the rising number of cancer cases would increase demand for gene therapies to treat cancer patients, which will in turn increase demand for plasmid DNA and viral vectors to produce these gene therapies.
By Region Insights: In 2024, North America market dominated the industry. This is due to a significant number of contract development firms in the area as well as the increasing involvement of businesses in gene and cell therapy research and product development. Furthermore, local businesses are growing their production plants in the area. Due to the use of highly creative manufacturing technologies for production and the existence of important market participants, such as CDMOs providing GMP manufacturing services, the United States held the largest revenue share in the North American viral vectors and plasmid DNA manufacturing market.
Market Competitive Landscape
The market leaders in the production of plasmid DNA and viral vectors are listed below. Together, these businesses control the majority of the market and set the direction of the sector. To map the supply network, the financials, strategy maps, and products of these enterprises that manufacture plasmid DNA and viral vectors are examined. Some of the prominent players in Global Viral Vector and Plasmid DNA Manufacturing Market are Audentes Therapeutics, Batavia Biosciences, BioMarin Pharmaceutical, BioNTech IMFS, Catalent Inc., Cobra Biologics, Genezen laboratories, Lonza, Miltenyi Biotec, RegenxBio, Inc.
Recent Developments:
- In February 2025, Boehringer Ingelheim, in partnership with IP Group, the UK Respiratory Gene Therapy Consortium, and Oxford Biomedica, initiated the LENTICLAIRâ„¢ 1 Phase I/II trial for BI 3720931. This innovative inhaled gene therapy aims to improve outcomes for individuals with cystic fibrosis, irrespective of the specific genetic mutations causing the disease.
- In February 2025, The Parenteral Drug Association (PDA) released "Points to Consider No. 11," a comprehensive document providing guidance on the development, classification, manufacture, control, and testing of plasmids and vectors used in Advanced Therapy Medicinal Products (ATMP) production.
- In July 2024, Kaneka Eurogentec achieved a milestone by producing one kilogram of plasmid DNA from a single fermentation run, setting a new benchmark in large-scale plasmid DNA manufacturing.
- In October 2023, AGC Biologics has stated that they will expand their pDNA manufacturing facility in Germany. This is expected to help the corporation decrease the time necessary for manufacturing.
- In February 2023, BioNTech SE announced the completion of its first plasmid DNA synthesis unit in Germany. This allows the company to produce pDNA independently for clinical and commercial uses.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Vector Type, By Workflow, By Application, By End Use, By Disease. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | Audentes Therapeutics, Batavia Biosciences, BioMarin Pharmaceutical, BioNTech IMFS, Catalent Inc., Cobra Biologics, Genezen laboratories, Lonza, Miltenyi Biotec, RegenxBio, Inc. |
Key Topics Covered in the Report
- Global Viral Vector and Plasmid DNA Manufacturing Market Size (FY’2021-FY’2034)
- Overview of Global Viral Vector and Plasmid DNA Manufacturing Market
- Segmentation of Global Viral Vector and Plasmid DNA Manufacturing Market By Vector Type (Adenovirus, Retrovirus, Adeno-Associated Virus (AAV), Lentivirus, Plasmids and Others)
- Segmentation of Global Viral Vector and Plasmid DNA Manufacturing Market By Workflow (Upstream Manufacturing and Downstream Manufacturing)
- Segmentation of Global Viral Vector and Plasmid DNA Manufacturing Market By Application (Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology and Research Applications)
- Segmentation of Global Viral Vector and Plasmid DNA Manufacturing Market By End Use (Pharmaceutical & Biopharmaceutical Companies and Research Institutes)
- Segmentation of Global Viral Vector and Plasmid DNA Manufacturing Market By Disease (Cancer, Genetic Disorders, Infectious Diseases and Others)
- Statistical Snap of Global Viral Vector and Plasmid DNA Manufacturing Market
- Expansion Analysis of Global Viral Vector and Plasmid DNA Manufacturing Market
- Problems and Obstacles in Global Viral Vector and Plasmid DNA Manufacturing Market
- Competitive Landscape in the Global Viral Vector and Plasmid DNA Manufacturing Market
- Details on Current Investment in Global Viral Vector and Plasmid DNA Manufacturing Market
- Competitive Analysis of Global Viral Vector and Plasmid DNA Manufacturing Market
- Prominent Players in the Global Viral Vector and Plasmid DNA Manufacturing Market
- SWOT Analysis of Global Viral Vector and Plasmid DNA Manufacturing Market
- Global Viral Vector and Plasmid DNA Manufacturing Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPERs internal database2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Viral Vector and Plasmid DNA Manufacturing Market Manufacturing Base Distribution, Sales Area, Interface Type6.2. Mergers & Acquisitions, Partnerships, Interface Launch, and Collaboration in Global Viral Vector and Plasmid DNA Manufacturing Market
7. Global Viral Vector and Plasmid DNA Manufacturing Market, By Vector Type 2021-2034 (USD Million)
7.1. Adenovirus7.2. Retrovirus7.3. Adeno-Associated Virus (AAV)7.4. Lentivirus7.5. Plasmids7.6. Others
8. Global Viral Vector and Plasmid DNA Manufacturing Market, By Workflow 2021-2034 (USD Million)
8.1. Upstream Manufacturing
8.1.1. Vector Amplification & Expansion8.1.2. Vector Recovery/Harvesting
8.2. Downstream Manufacturing
8.2.1. Purification8.2.2. Fill Finish
9. Global Viral Vector and Plasmid DNA Manufacturing Market, By Application 2021-2034 (USD Million)
9.1. Antisense & RNAi Therapy9.2. Gene Therapy9.3. Cell Therapy9.4. Vaccinology9.5. Research Applications
10. Global Viral Vector and Plasmid DNA Manufacturing Market, By End Use 2021-2034 (USD Million)
10.1. Pharmaceutical and Biopharmaceutical Companies10.2. Research Institutes
11. Global Viral Vector and Plasmid DNA Manufacturing Market, By Disease 2021-2034 (USD Million)
11.1. Cancer11.2. Genetic Disorders11.3. Infectious Diseases11.4. Others
12. Global Viral Vector and Plasmid DNA Manufacturing Market, 2021-2034 (USD Million)
12.1. Global Viral Vector and Plasmid DNA Manufacturing Market Size and Market Share
13. Global Viral Vector and Plasmid DNA Manufacturing Market, By Region, 2021-2034 (USD Million)
13.1. Asia-Pacific
13.1.1. Australia13.1.2. China13.1.3. India13.1.4. Japan13.1.5. South Korea13.1.6. Rest of Asia-Pacific
13.2. Europe
13.2.1. France13.2.2. Germany13.2.3. Italy13.2.4. Spain13.2.5. United Kingdom13.2.6. Rest of Europe
13.3. Middle East and Africa
13.3.1. Kingdom of Saudi Arabia13.3.2. United Arab Emirates13.3.3. Qatar13.3.4. South Africa13.3.5. Egypt13.3.6. Morocco13.3.7. Nigeria13.3.8. Rest of Middle-East and Africa
13.4. North America
13.4.1. Canada13.4.2. Mexico13.4.3. United States
13.5. Latin America
13.5.1. Argentina13.5.2. Brazil13.5.3. Rest of Latin America
14. Company Profile
14.1. Audentes Therapeutics
14.1.1. Company details14.1.2. Financial outlook14.1.3. Interface summary14.1.4. Recent developments
14.2. Batavia Biosciences
14.2.1. Company details14.2.2. Financial outlook14.2.3. Interface summary14.2.4. Recent developments
14.3. BioMarin Pharmaceutical
14.3.1. Company details14.3.2. Financial outlook14.3.3. Interface summary14.3.4. Recent developments
14.4. BioNTech IMFS
14.4.1. Company details14.4.2. Financial outlook14.4.3. Interface summary14.4.4. Recent developments
14.5. Catalent Inc.
14.5.1. Company details14.5.2. Financial outlook14.5.3. Interface summary14.5.4. Recent developments
14.6. Cobra Biologics
14.6.1. Company details14.6.2. Financial outlook14.6.3. Interface summary14.6.4. Recent developments
14.7. Genezen Laboratories
14.7.1. Company details14.7.2. Financial outlook14.7.3. Interface summary14.7.4. Recent developments
14.8. Lonza
14.8.1. Company details14.8.2. Financial outlook14.8.3. Interface summary14.8.4. Recent developments
14.9. Miltenyi Biotec
14.9.1. Company details14.9.2. Financial outlook14.9.3. Interface summary14.9.4. Recent developments
14.10. RegenxBio Inc.
14.10.1. Company details14.10.2. Financial outlook14.10.3. Interface summary14.10.4. Recent developments
14.11. Others
15. Conclusion
16. List of Abbreviations
17. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Viral vector and plasmid DNA manufacturing are critical processes in gene therapy, vaccine development, and cell-based treatments, enabling the delivery of genetic material into target cells for therapeutic applications. The market is experiencing rapid growth due to increasing demand for gene and cell therapies, advancements in biotechnology, and the rise of mRNA-based vaccines.
Viral Vector and Plasmid DNA Manufacturing Market size is USD 41.3 billion from 2025 to 2034.
Viral Vector and Plasmid DNA Manufacturing Market is covered By Product, By Function, By Application, By End-User.
The North America is anticipated to have the highest Market share in the Viral Vector and Plasmid DNA Manufacturing Market.
The key players in the Market include Companies Covered Audentes Therapeutics, Batavia Biosciences, BioMarin Pharmaceutical, BioNTech IMFS, Catalent Inc., Cobra Biologics, Genezen laboratories, Lonza, Miltenyi Biotec, RegenxBio, Inc.
Viral Vector and Plasmid DNA Manufacturing Market is projected to reach USD 41.3 billion by 2034, growing at a CAGR of 20.46% during the forecast period.
Viral Vector and Plasmid DNA Manufacturing Market grew in Market size from 2025. The Market is expected to reach USD 41.3 billion by 2034, at a CAGR of 20.46% during the forecast period.
Viral Vector and Plasmid DNA Manufacturing Market CAGR of 20.46% during the forecast period.
You can get the sample pages by clicking the link - Click Here
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
